Legend Biotech Yönetim

Yönetim kriter kontrolleri 1/4

Legend Biotech CEO'su Ying Huang, Sep2020 tarihinde atandı, in görev süresi 4.25 yıldır. şirketin hisselerinin 0.035% doğrudan sahiptir ve bu hisselerin değeri $ 2.09M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 3.5 yıldır.

Anahtar bilgiler

Ying Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.3yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

Legend Biotech: The Story Brightens

Dec 05

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

CEO

Ying Huang (51 yo)

4.3yrs

Görev süresi

Dr. Ying Huang, Ph D., is Chief Executive Officer of Legend Biotech Corporation since November 06, 2020 and serves as its Director since December 2021. He had been Chief Financial Officer of Legend Biotech...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Huang	CEO & Director	4.3yrs	Veri yok	0.035% $ 2.1m
Lori Macomber	Chief Financial Officer	2.6yrs	Veri yok	0.0031% $ 183.0k
Doug Wallace	Vice President of Global Operations	1.1yrs	Veri yok	Veri yok
Guowei Fang	Chief Scientific Officer & Head of Business Development	no data	Veri yok	Veri yok
Joanne Choi	Senior Manager of Investor Relations	no data	Veri yok	Veri yok
James Pepin	General Counsel	1.1yrs	Veri yok	Veri yok
Tim Roberts	Global Compliance Officer	less than a year	Veri yok	Veri yok
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	no data	Veri yok	Veri yok
Elaine Qian	VP & Global Head of Human Resources	1.7yrs	Veri yok	Veri yok
Yuhong Qiu	Senior Vice President of Global Regulatory Affairs	2.9yrs	Veri yok	Veri yok
Alan Kick	Senior Vice President of Global Quality	2.9yrs	Veri yok	Veri yok
Mythili Koneru	Chief Medical Officer	1.7yrs	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: LEGN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Huang	CEO & Director	3yrs	Veri yok	0.035% $ 2.1m
John M. Maraganore	Member of Strategic Advisory Board	1.7yrs	Veri yok	Veri yok
Li Zhu	Non-Independent Director	4.1yrs	Veri yok	Veri yok
Corazon Sanders	Independent Director	4.6yrs	Veri yok	0.010% $ 623.4k
Xiaohui Ji	Independent Director	4.6yrs	Veri yok	0.0050% $ 299.2k
Tomas Heyman	Independent Director	2.3yrs	Veri yok	0.0011% $ 66.2k
Fangliang Zhang	Independent Chairman	2.3yrs	Veri yok	0% $ 0
Ye Wang	Director	9.6yrs	Veri yok	0% $ 0
Michel Vounatsos	Member of Strategic Advisory Board	1.7yrs	Veri yok	Veri yok
Wai Man Yau	Independent Director	4.6yrs	Veri yok	0.0010% $ 60.8k
Patrick Casey	Independent Director	4yrs	Veri yok	0.0069% $ 411.3k
Li Mao	Independent Director	2.3yrs	Veri yok	0.0019% $ 112.6k

3.5yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LEGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/30 19:29
Gün Sonu Hisse Fiyatı	2024/12/30 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Legend Biotech Corporation 27 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
Konstantinos Biliouris	BMO Capital Markets Equity Research

Legend Biotech Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Recent updates

Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study

Legend Biotech: The Story Brightens

Consensus EPS estimates upgraded to US$1.28 loss

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

Consensus EPS estimates fall by 14%, revenue upgraded

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Consensus estimates of losses per share improve by 33%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.